Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALOMID vs POMBILITI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
FDA approved: Newly diagnosed multiple myeloma (in combination with dexamethasone),FDA approved: Moderate to severe erythema nodosum leprosum (ENL) in leprosy,Off-label: Crohn's disease,Off-label: Bechet's disease,Off-label: HIV-associated wasting syndrome,Off-label: Recurrent aphthous ulcers
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
500 mg orally twice daily
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Thalidomide is primarily metabolized by spontaneous hydrolysis in plasma and tissues, not by cytochrome P450 enzymes. Minor metabolism involves hydroxylation and conjugation.
Primarily metabolized by CYP3A4, CYP2C8, and CYP2C9; also undergoes glucuronidation. The active metabolite, GFT505, is formed via hydrolysis.
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Approximately 55-66% bound to serum albumin.
>99% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent Vd is 0.7-1.2 L/kg, suggesting distribution into total body water with some tissue binding.
Volume of distribution is approximately 2000 L (>25 L/kg), indicating extensive extravascular distribution and tissue binding.
Oral bioavailability is >90% with minimal first-pass metabolism.
Oral bioavailability is approximately 25% (range 15–35%) due to first-pass metabolism; may increase with high-fat meal.
For GFR 30-60 m L/min: reduce dose by 50%; for GFR <30 m L/min or dialysis: administer 100 mg once daily; for severe renal impairment, consider alternative therapy.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 250 mg twice daily; GFR <15 m L/min or dialysis: 250 mg once daily
Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: use with caution, consider dose reduction; limited data for severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended
Not recommended for use in children <18 years due to lack of safety and efficacy data; in clinical trials for specific conditions (e.g., recurrent brain tumors), doses of 3-6 mg/kg/day have been used, but not approved.
Weight <40 kg: 10 mg/kg orally twice daily (max 500 mg/dose); Weight ≥40 kg: 500 mg twice daily
Start at lower end of dosing range (e.g., 100 mg daily) due to increased sensitivity to sedation and thromboembolic risk; monitor renal function as elderly often have decreased GFR.
No specific adjustment required; monitor renal function and consider age-related decline in GFR
THALOMID is contraindicated in pregnancy due to severe life-threatening birth defects. It must never be used by females who are pregnant or could become pregnant. If thalidomide is used during pregnancy, it can cause severe birth defects or death of the fetus. Additionally, females of reproductive potential must use two effective forms of contraception or abstain from heterosexual intercourse for at least 4 weeks before starting therapy, during therapy, and for 4 weeks after discontinuing therapy.
None.
Venous thromboembolic events (VTE) – increased risk, especially when combined with dexamethasone,Fetal exposure – requires patient enrollment in the THALOMID REMS program,Hypersensitivity reactions – including rash, Stevens-Johnson syndrome,Peripheral neuropathy – may be irreversible, monitor for symptoms,Somnolence and dizziness – may impair ability to drive or operate machinery,Syncope and bradycardia – may occur, especially in elderly,Hepatotoxicity – monitor liver function tests,Hematologic toxicity – neutropenia and thrombocytopenia,Seizures – use with caution in patients with history of seizures
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests before and during treatment.,Myopathy: Risk of muscle injury; assess creatine kinase if muscle symptoms occur.,Gallbladder-related events: Increased risk of cholelithiasis and cholecystitis.,Fetal risk: Based on animal data, may cause fetal harm; advise effective contraception in females of reproductive potential.,Renal impairment: Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Pregnancy or women of childbearing potential not using two forms of contraception,Hypersensitivity to thalidomide or any component of the formulation,Use in females who are breastfeeding (contraindicated due to potential harm to infant)
Hypersensitivity to elafibranor or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Take with water on an empty stomach (at least 1 hour before or 2 hours after meals). Avoid grapefruit juice, alcohol, and high-fat meals as they may alter absorption and increase risk of side effects.
No known food interactions. Maintain a balanced diet as recommended by a healthcare provider. There are no specific dietary restrictions required with Pombiliti.
Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart disease, and anotia. No safe gestational trimester exists; contraindicated in pregnancy.
Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show embryolethality and teratogenicity at subclinical doses.
Excretion into breast milk unknown. Due to potential for adverse effects in the nursing infant, breastfeeding is contraindicated. M/P ratio not available.
No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression, myelosuppression), breastfeeding is not recommended during therapy and for at least 3 months after last dose.
Contraindicated in pregnancy; no dose adjustments applicable because thalidomide is absolutely contraindicated during pregnancy.
No dose adjustment recommendations are possible; Pombiliti is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not studied due to contraindication. No specific dosing guidelines exist for pregnant patients.
Thalomid (thalidomide) is a potent teratogen requiring strict pregnancy prevention. It has immunomodulatory, anti-inflammatory, and anti-angiogenic properties. Used primarily for erythema nodosum leprosum (ENL) and multiple myeloma. Monitor for thromboembolic events, peripheral neuropathy, and bradycardia. Dose adjustment needed for hepatic impairment. Ensure patient enrollment in THALOMID REMS program.
Pombiliti (cipaglucosidase alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy for Pompe disease. Do not confuse with alglucosidase alfa (Myozyme/Lumizyme). Requires premedication with antihistamines and antipyretics due to risk of infusion-associated reactions (IARs). Monitor for anaphylaxis, particularly during initial infusions. Administer by IV infusion over approximately 4 hours. Use a low-protein-binding infusion set with an in-line low-protein-binding filter. May cause rapid deterioration in patients with cardiac hypertrophy; monitor cardiac function before and during treatment.
Thalidomide can cause severe birth defects; use two forms of contraception during treatment and for 4 weeks after stopping.,Do not take during pregnancy or if planning to become pregnant; male patients must use condoms during sexual activity.,Report any numbness, tingling, or pain in hands/feet immediately.,Seek emergency care for signs of blood clots: chest pain, shortness of breath, leg swelling, or vision changes.,Avoid alcohol and grapefruit juice as they may increase side effects.,Do not donate blood or sperm while on therapy and for 4 weeks after discontinuation.
Inform your healthcare provider immediately if you experience hives, itching, difficulty breathing, swelling, chest tightness, or fever during or after the infusion.,You may receive premedications (such as antihistamines and acetaminophen) before your infusion to reduce the risk of allergic reactions.,Do not miss your scheduled infusions; regular treatment is necessary to manage Pompe disease.,Report any new or worsening muscle weakness, breathing difficulties, or heart-related symptoms.,Keep a list of all medications you take, including over-the-counter drugs and supplements, and share it with your doctor.,Pombiliti is not a cure; it is an enzyme replacement therapy to reduce symptoms and slow disease progression.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALOMID vs POMBILITI, answered by our medical review team.
THALOMID is a Immunomodulatory Agent that works by Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).. POMBILITI is a Immunomodulatory Agent that works by POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALOMID and POMBILITI depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALOMID is: 200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.. The standard adult dose of POMBILITI is: 500 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALOMID and POMBILITI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALOMID is classified as Category C. Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart d. POMBILITI is classified as Category C. Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.